KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Non-Current Deffered Revenue (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 17 years of Non-Current Deffered Revenue data on record, last reported at $107.9 million in Q3 2025.

  • For Q3 2025, Non-Current Deffered Revenue fell 37.91% year-over-year to $107.9 million; the TTM value through Sep 2025 reached $107.9 million, down 37.91%, while the annual FY2024 figure was $156.5 million, 35.11% down from the prior year.
  • Non-Current Deffered Revenue reached $107.9 million in Q3 2025 per IONS's latest filing, down from $125.1 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $402.0 million in Q1 2021 and bottomed at $107.9 million in Q3 2025.
  • Average Non-Current Deffered Revenue over 5 years is $255.4 million, with a median of $254.4 million recorded in 2023.
  • Peak YoY movement for Non-Current Deffered Revenue: decreased 14.08% in 2021, then crashed 37.91% in 2025.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $351.9 million in 2021, then decreased by 18.22% to $287.8 million in 2022, then fell by 16.19% to $241.2 million in 2023, then plummeted by 35.11% to $156.5 million in 2024, then tumbled by 31.05% to $107.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Deffered Revenue were $107.9 million in Q3 2025, $125.1 million in Q2 2025, and $140.7 million in Q1 2025.